Hit-to-Lead in Academia: Discovery of a Protein-Protein Interaction Inhibitor of Keap1-Nrf2

Daisuke Yasuda, Rika Obata, Kyoko Takahashi, Tomoyuki Ohe, Tadahiko Mashino

Research output: Contribution to journalReview article

Abstract

 In the process of recent hit-to-lead studies, not only in industry but also in academia, early evaluation of metabolic properties has been one of the key aspects supporting a higher probability of success in drug discovery. In this review, we introduce the development of chemical seeds targeting the Kelch-like ECH-associated protein-1 (Keap1) as an example of an academic hit-to-lead study considering metabolic stability. Keap1 regulates the function of nuclear factor erythroid 2-related factor 2 (Nrf2), which induces various antioxidative or detoxification proteins. An inhibitor of protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 is expected to be a novel target for drug discovery. However, Nrf2 is also activated in several cancers, such as human hepatocellular carcinoma, and causes chemoresistance, which is mediated by phosphorylated p62/Sqstm1 (p-p62), an autophagy-related protein that also undergoes a PPI with Keap1. In this case, an Nrf2 suppressor could be used to attenuate drug resistance. We discovered inhibitors against the Nrf2-Keap1 PPI and p-p62-Keap1 PPI using high-throughput screening and established the synthetic routes for the hit compounds and their derivatives. Furthermore, we assessed the metabolic stability of both of the PPI inhibitors in human liver microsomes and identified the metabolic sites.

Original languageEnglish
Pages (from-to)1059-1065
Number of pages7
JournalYakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Volume138
Issue number8
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Proteins
Drug Discovery
Kelch-Like ECH-Associated Protein 1
Lead
Protein Stability
Liver Microsomes
Drug Resistance
Hepatocellular Carcinoma
Seeds
Industry
Neoplasms

Keywords

  • drug discovery
  • metabolic stability
  • p62
  • protein-protein interaction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Hit-to-Lead in Academia : Discovery of a Protein-Protein Interaction Inhibitor of Keap1-Nrf2. / Yasuda, Daisuke; Obata, Rika; Takahashi, Kyoko; Ohe, Tomoyuki; Mashino, Tadahiko.

In: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Vol. 138, No. 8, 01.01.2018, p. 1059-1065.

Research output: Contribution to journalReview article

@article{28a0d646bc4847e59c73dd245f7b226b,
title = "Hit-to-Lead in Academia: Discovery of a Protein-Protein Interaction Inhibitor of Keap1-Nrf2",
abstract = " In the process of recent hit-to-lead studies, not only in industry but also in academia, early evaluation of metabolic properties has been one of the key aspects supporting a higher probability of success in drug discovery. In this review, we introduce the development of chemical seeds targeting the Kelch-like ECH-associated protein-1 (Keap1) as an example of an academic hit-to-lead study considering metabolic stability. Keap1 regulates the function of nuclear factor erythroid 2-related factor 2 (Nrf2), which induces various antioxidative or detoxification proteins. An inhibitor of protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 is expected to be a novel target for drug discovery. However, Nrf2 is also activated in several cancers, such as human hepatocellular carcinoma, and causes chemoresistance, which is mediated by phosphorylated p62/Sqstm1 (p-p62), an autophagy-related protein that also undergoes a PPI with Keap1. In this case, an Nrf2 suppressor could be used to attenuate drug resistance. We discovered inhibitors against the Nrf2-Keap1 PPI and p-p62-Keap1 PPI using high-throughput screening and established the synthetic routes for the hit compounds and their derivatives. Furthermore, we assessed the metabolic stability of both of the PPI inhibitors in human liver microsomes and identified the metabolic sites.",
keywords = "drug discovery, metabolic stability, p62, protein-protein interaction",
author = "Daisuke Yasuda and Rika Obata and Kyoko Takahashi and Tomoyuki Ohe and Tadahiko Mashino",
year = "2018",
month = "1",
day = "1",
doi = "10.1248/yakushi.17-00211-5",
language = "English",
volume = "138",
pages = "1059--1065",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

TY - JOUR

T1 - Hit-to-Lead in Academia

T2 - Discovery of a Protein-Protein Interaction Inhibitor of Keap1-Nrf2

AU - Yasuda, Daisuke

AU - Obata, Rika

AU - Takahashi, Kyoko

AU - Ohe, Tomoyuki

AU - Mashino, Tadahiko

PY - 2018/1/1

Y1 - 2018/1/1

N2 -  In the process of recent hit-to-lead studies, not only in industry but also in academia, early evaluation of metabolic properties has been one of the key aspects supporting a higher probability of success in drug discovery. In this review, we introduce the development of chemical seeds targeting the Kelch-like ECH-associated protein-1 (Keap1) as an example of an academic hit-to-lead study considering metabolic stability. Keap1 regulates the function of nuclear factor erythroid 2-related factor 2 (Nrf2), which induces various antioxidative or detoxification proteins. An inhibitor of protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 is expected to be a novel target for drug discovery. However, Nrf2 is also activated in several cancers, such as human hepatocellular carcinoma, and causes chemoresistance, which is mediated by phosphorylated p62/Sqstm1 (p-p62), an autophagy-related protein that also undergoes a PPI with Keap1. In this case, an Nrf2 suppressor could be used to attenuate drug resistance. We discovered inhibitors against the Nrf2-Keap1 PPI and p-p62-Keap1 PPI using high-throughput screening and established the synthetic routes for the hit compounds and their derivatives. Furthermore, we assessed the metabolic stability of both of the PPI inhibitors in human liver microsomes and identified the metabolic sites.

AB -  In the process of recent hit-to-lead studies, not only in industry but also in academia, early evaluation of metabolic properties has been one of the key aspects supporting a higher probability of success in drug discovery. In this review, we introduce the development of chemical seeds targeting the Kelch-like ECH-associated protein-1 (Keap1) as an example of an academic hit-to-lead study considering metabolic stability. Keap1 regulates the function of nuclear factor erythroid 2-related factor 2 (Nrf2), which induces various antioxidative or detoxification proteins. An inhibitor of protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 is expected to be a novel target for drug discovery. However, Nrf2 is also activated in several cancers, such as human hepatocellular carcinoma, and causes chemoresistance, which is mediated by phosphorylated p62/Sqstm1 (p-p62), an autophagy-related protein that also undergoes a PPI with Keap1. In this case, an Nrf2 suppressor could be used to attenuate drug resistance. We discovered inhibitors against the Nrf2-Keap1 PPI and p-p62-Keap1 PPI using high-throughput screening and established the synthetic routes for the hit compounds and their derivatives. Furthermore, we assessed the metabolic stability of both of the PPI inhibitors in human liver microsomes and identified the metabolic sites.

KW - drug discovery

KW - metabolic stability

KW - p62

KW - protein-protein interaction

UR - http://www.scopus.com/inward/record.url?scp=85051467351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051467351&partnerID=8YFLogxK

U2 - 10.1248/yakushi.17-00211-5

DO - 10.1248/yakushi.17-00211-5

M3 - Review article

C2 - 30068847

AN - SCOPUS:85051467351

VL - 138

SP - 1059

EP - 1065

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 8

ER -